HARMONi-6
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
- NCT05840016 ↗
- Active, not recruiting
- Akeso
- Deep
We haven't built an HCP commentary report on HARMONi-6 (AK112 and tislelizumab in Advanced Squamous Non Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses HARMONi-6’s comparison of ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in advanced squamous NSCLC, and the rationale of combining PD-1 and VEGF targeting. Questions raised include whether the overall-survival pattern will persist at final analysis, how findings may translate beyond the study population, and how to interpret the older-patient signal. Discussion also covers bleeding-related eligibility exclusions, including hemoptysis, cavitation and vessel involvement, and their implications for patient selection.
Indexed commentary on HARMONi-6 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 134 | |
| YouTube | 14 | |
| Podcasts | 11 | |
| Bluesky threads | 8 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Combined With Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Advanced Squamous Non Small Cell Lung Cancer
- Interventions
- AK112, Carboplatin, Paxlitaxel; Tislelizumab, Carboplatin, Paxlitaxel
- Arms
- Experimental: AK112 in Combination With Paclitaxel Plus Carboplatin · Experimental
- Active Comparator: Tislelizumab in Combination With Paclitaxel Plus Carboplatin · Active comparator
- Enrollment
- 532
- Primary outcomes
- PFS assessed by IRRC per RECIST v1.1
- Sponsor
- Akeso
- Start
- Aug 17, 2023
- Primary completion
- Feb 28, 2025
- Results posted
- No
- Registry record
- NCT05840016 · updated May 2, 2025
Publications
linked from the registry- Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Moore AC, Lu S. Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study. Future Oncol. 2026 Jun;22(14):1637-1650. doi: 10.1080/14796694.2026.2676052. Epub 2026 Jun 3. PubMed 42233228
- Lu S, Liu B, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Chen Z, Li W, Lu D, Hu M, Wang ZM, Li B, Xia MY. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet. 2026 Jun 27;407(10548):2620-2629. doi: 10.1016/S0140-6736(26)00966-9. Epub 2026 May 31. PubMed 42218899